In mid-February, the American Society of Breast Surgeons updated its position on genetic testing, recommending that it be made available to all patients with breast cancer; this is a big departure from the society’s 2017 guidelines, which were similar to the National Comprehensive Cancer Network’s more restrictive guidelines.
“We are seeing more data that suggests the current NCCN guidelines miss a fair number of patients with genetic mutations: pathogenic